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Abstract. Increased left ventricular myocardial mass 
(LVM) is a well known prognostic marker of poor cardiac 
outcomes. Decreases in LVM have been shown to decrease 
the cardiovascular risk. Aged garlic extract (AGE) has 
been shown to have an overall favorable effect on cardiac 
health; however, to the best of our knowledge, no study to 
date has specifically examined its effects on left ventricular 
mass. This study investigated whether AGE can affect LVM 
measured by cardiac computed tomography angiography 
(CCTA) in patients with diabetes mellitus (DM). This is a 
double-blind, placebo controlled randomized trial. In total, 
65 participants with DM with a mean age of 58 years were 
prospectively assigned to consume 2,400 mg AGE/day or the 
placebo orally. Both groups underwent CCTA at baseline 
and follow-up at 1 year apart. LVM was measured using 
automated software. The baseline characteristics did not 
differ between the AGE and placebo groups. There was a 
trend towards a significant reduction in LVM at follow‑up 
as compared to baseline in the AGE group (119.30±34.77 
vs. 121.0±34.70, P=0.059). No change was observed in LVM 
in the placebo group at 1-year follow-up as compared to base-
line (124.6±37.33 vs. 124.6±35.13, P=0.9). On the whole, this 
study indicated that AGE may decrease or stabilize LVM. 
Further studies however, with a larger sample size and longer 
follow-up times are required to evaluate the effects of AGE 
on hypertension and LVM.
Introduction
Left ventricular hypertrophy (LVH) is a relatively common 
cardiomyopathy. The prevalence of LVH in the general popu-
lation has been estimated at 12.9-16% for males and 9.1-19% 
for females (1,2). The prevalence increases markedly with 
age (1), the diagnosis of hypertension (3) and the diagnosis of 
diabetes (4). LVH and increased left ventricular mass (LVM) 
is furthermore a known predictor of poor cardiovascular 
outcomes, including sudden cardiac death (5), ventricular 
arrhythmias (6), and heart failure (7). However, LVH appears 
to be somewhat reversible, with studies demonstrating a 
decreased left ventricular myocardial mass (LVM) with a 
reduction in blood pressure (8), as well as exercise and weight 
loss (9). Importantly, reductions in LVM appear to reduce risk 
of poor cardiovascular outcomes in several studies (10).
Aged garlic extract (AGE) is a supplement with several 
known medicinal qualities. As regards cardiovascular health, 
garlic supplementation has been shown to lower total choles-
terol levels (11), blood pressure (12) and to prevent oxidative 
DNA damage in essential hypertension (13). AGE has also 
been shown to attenuate the progression of coronary athero-
sclerosis, improve vascular function and exert favorable effects 
on oxidative biomarkers (14,15). However, to the best of our 
knowledge, no studies available to date have examined the 
effects of AGE on LVM. Thus, the present placebo-controlled 
randomized double blinded study, examined the effects of 
AGE on LVM in subjects with diabetes mellitus (DM) using 
serial contrasted coronary CT scans.
Subjects and methods
Study design. The present study is a single center randomized, 
placebo-controlled, double-blind comparison of AGE 
(2,400 mg daily) compared to matching placebo capsules 
(ClinicalTrials.gov ID: NCT01534910). As previously 
described (15), AGE (Kyolic), provided by Wakunaga of 
America, was formulated by soaking sliced raw garlic in 
aqueous ethanol for up to 20 months at room temperature. The 
extract was then filtered and concentrated at a low temperature. 
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The AGE used in this trial contained 305 g extracted 
solids/L. The finished product used in this clinical study was 
commercially available. The participants were assigned to 
AGE or placebo in a double-blinded manner, using numbered 
containers assigned to a computer-generated randomization 
chart by a nurse coordinator. The subjects were observed on 
therapy for 52 weeks. The subjects had study-related visits 
quarterly (at 13, 26, 29 and 52 weeks) where they were assessed 
for compliance and adverse events.
Imaging and laboratory data. Laboratory data, including 
complete blood count, chemistry panel, hemoglobin A1c levels 
and inflammatory biomarkers were collected at weeks 1, 26 
and 52. At baseline and week 52, the subjects underwent 
non-contrast CT and coronary CT angiography using a 
64-slice multi-detector scanner. Sublingual nitroglycerin or 
nitroglycerin spray 0.4 mg was administered prior to the scan. 
Prescan beta-blockers were also administered to achieve a 
resting heart rate of <60 beats/min. Quantitative data analyses 
were performed using automated methods on a workstation 
and software (AW 4.6; GE Medical Systems) that used a 
Hounsfield unit‑based endocardial border detection technique. 
Images were reconstructed with a slice thickness of 1.25 mm. 
LVM was also simultaneously calculated automatically. The 
mid-diastolic phases were chosen for measurement of LVM. 
The user acquiring the measurements was blind to participant 
characteristics and randomization status of each subject. The 
use of contrast CT for the measurement of chamber size and 
LVM has been validated in previous studies (16,17).
Patient population. The patients were males and females aged 
30‑75 years with known DM (defined as hemoglobin A1c levels, 
>6.5%; fasting blood sugar levels, >125 mg/dl; and/or taking 
anti-diabetes medications) with a coronary calcium score 
of >20 at baseline and who consented to the study design. This 
study was approved by the local IRB (Los Angeles Biomedical 
research Center). Notable exclusion criteria included a known 
allergy to AGE, a body weight >350 pounds, bleeding disor-
ders, a history of known coronary artery disease (CAD), any 
malignancy within the past 5 years and serum creatinine levels 
>1.4 mg/dl.
Statistical analysis. Demographic and clinical charac-
teristics were determined at the baseline time point and 
Table I. Baseline characteristics of the study subjects by treatment arm.
Characteristic Placebo (n=29) Active (n=36) P-value
Age, (mean ± SD), years   58.7±11.4   59.4±11.2 0.808 
BMI (mean ± SD), kg/m2 30.8±6.0 30.0±5.6 0.567 
Sex, male, n (%) 21 (72) 18 (50) 0.067 
Race, Hispanic, n (%)   9 (31) 14 (39) 0.284 
Hypertension, n (%) 15 (52) 23 (64) 0.323 
Taking anti-hypertensive medication, n (%) 15 (52) 23 (64) 0.323 
Hyperlipidemia, n (%)    24 (83%)    33 (92%) 0.277 
Taking anti-hyperlipidemia medication, n (%)    24 (83%)    33 (92%) 0.277 
Family history of heart disease, n (%)    14 (48%)    11 (31%) 0.144 
Post-menopausal, n (%)      7 (24%)    13 (36%) 0.299 
Previous smoker, n (%)    11 (38%)    15 (42%) 0.760 
Present smoker, n (%)      5 (17%)    2 (6%) 0.131 
Taking aspirin, n (%)    21 (72%)    21 (58%) 0.238 
SBP (mean ± SD), mmHg 126.59±15.55   131.0±18.35 0.307 
DBP (mean ± SD), mmHg 76.86±9.57 79.11±9.59 0.350 
Heart rate (mean ± SD), mmHg   71.07±12.91 69.11±9.09 0.493 
Adiponectin (mean ± SD), μg/dl   10.01±11.01   9.22±5.75 0.872 
HDL cholesterol (mean ± SD), mg/dl   40.10±12.56   40.11±11.14 0.293 
LDL cholesterol calculated (mean ± SD), mg/dl   72.55±33.10   66.56±27.34 0.695 
non-LDL cholesterol (mean ± SD), mg/dl 100.17±42.76   89.97±29.31 0.757 
Total cholesterol (mean ± SD), mg/dl 140.28±45.35 130.08±29.75 0.872 
hsCRP (mean ± SD), mg/l   3.47±3.90   2.26±2.15 0.933 
Interleukin 6 (mean ± SD), ng/ml   2.37±1.89   2.60±4.52 0.504 
Lp-PLA2 (mean ± SD), ng/ml   41.17±15.04   36.47±13.14 0.695 
Oxidized LDL (mean ± SD), U/l   28.69±10.60 24.97±8.07 0.923 
Triglycerides (mean ± SD), mg/dl 138.76±79.38 116.92±54.47 0.807 
SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; hsCRP, high sensi-
tivity C-reactive protein; Lp-PLA2, lipoprotein-associated phospholipase A2.
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compared by randomization status. A Student's t-test or 
Chi-square test was used to assess the differences in all 
baseline parameters. Continuous variables are expressed as 
the means ± SD, while categorical variables are stated as 
counts and percentages. For the primary outcome (change 
in left ventricular mass over time), an analysis of variance 
(ANOVA) model with Tukey's post hoc test was used to 
compare the treatment arm versus placebo. Analyses was 
performed on an intention-to-treat basis. SAS software 
(version 9.4; SAS Institute, Inc.) was used to carry out all 
statistical analyses.
Results
A total of 65 diabetic patients successfully completed the 
1-year study and received a baseline and follow-up CT, 
including 29 patients in the placebo arm and 36 patients in the 
active treatment (AGE) arm. The baseline characteristics were 
similar between the 2 groups (Table I). The average age in 
the placebo group was 58.7 years and 59.4 years in treatment 
group (P=0.808). A higher number of subjects in the placebo 
group were male (72% of patients vs. 50% in the treatment 
arm), although this was not statistically significant (P=0.067). 
Body mass index (BMI) was similar between the groups 
(30.8 vs. 30.0 kg/m2, P=0.567). The subjects in both groups 
were generally at a high cardiovascular risk with hyperten-
sion being 52% in the placebo arm and 64% in the treatment 
arm (P=0.323); and hyperlipidemia being 83% in the placebo 
arm vs. 92% in the treatment arm (P=0.277). The cholesterol 
levels and inflammatory marker levels measured were similar 
between groups. All patients were diabetic as per the study 
protocol. All the patient baseline characteristics are presented 
in Table I.
The baseline mean LVM was similar between groups 
(121.0 g in treatment arm vs. 124.0 g in the placebo arm, 
P=0.69). At follow-up scans, the mean LVM in the treatment 
arm decreased to 119 g (1.65% decrease) and the mean LVM 
in the placebo arm was similar at 124.6 g (0.48% increase). 
The decrease in LVM in the treatment arm trended towards 
statistical significance (P=0.059). The change in LVM in 
the placebo arm was not statistically significant (P=0.97). 
The mean difference in absolute change between the groups 
was not statistically significant (‑1.68 g in the treatment arm 
vs. 0.04 g in the placebo arm, P=0.30) (Table II).
Discussion
In the present study, a trend towards a decreased LVM was 
observed in patients undergoing 1 year of treatment with AGE, 
with a reduction of mass of 1.65%. The same trend was not 
observed in the placebo arm, in which the LVM was essen-
tially unaltered following 1 year of placebo therapy (increased 
by 0.48%). These results suggest an effect of AGE in reducing 
LVM; however, studies with larger sample sizes are warranted 
to confirm these findings.
AGE is known to decrease blood pressure (12,18) which in 
turn, is known to reduce left ventricular mass (8). A reduction 
in blood pressure may indeed be the mechanism behind the 
observed effects. AGE may also have a direct effect on cardio-
myocytes that has yet to be determined. AGE has also been 
demonstrated to improve endothelial function, which may 
reduce afterload and stress on the myocardium (19). Finally, 
AGE reduces inflammation and this in turn my improve 
myocardial mass and induce regression (20).
This study has several limitations. Firstly, the sample size 
was small, and may not have been powerful enough to detect a 
statistically significant effect of AGE on LVM. Second, it was 
only a 1-year study, and it may take a longer period of time to 
observe the full effects of AGE on myocardial mass changes. 
Third, the population cohort was predominantly male and 
Hispanic, which limits generalizability. Future research is 
required in order to include similar trials with larger sample 
sizes and longer duration in order to better understand the 
trend observed in the current study.
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Table II. Left ventricular mass by treatment arm.
   Within Between
   group group
 Baseline Follow-up change change
 ----------------------------------------------------------------------- ------------------------------------------------------------------------- ------------------ ------------------
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